East and North Asia

Alcon Pharmaceutical Facility,
Alcon produces a wide range of products for ophthalmic patients, including eye drops and intraocular lenses.	The market for Alcon's products in the Asian market is increasing by about 20% per year.	The new Alcon plant in Singapore will produce pharmaceuticals such as moxifloxacin.
The Tuas Biomedical Park is one of Singapore's growth areas, despite a recent slump mainly due to the global credit crisis.	Travatan (travoprost) is one of the company's bestselling ophthalmic products.

AstraZeneca Pharmaceutical Manufacturing Plant, Wuxi
Astra Zeneca's Facility in Wuxi near Shanghai of Jiangsu China.	Chart showing health expenditure as a percentage of GDP.	The city of Shanghai is a good location for AstraZeneca as its economy is growing at fantastic pace.
The new packaging line at the Wuxi plant will allow 40 million more units per year to be packaged.

Bipha Human Serum Albumin Plant,
Location of Chitose: site of the world´s first human serum albumin plant.	A molecule of human serum albumin, the world's most-used intravenous protein.

Boehringer Ingelheim
Boehringer Ingelheim's new pharmaceutical manufacturing facility in Shanghai was opened in March 2002.	Tablets manufactured in Shanghai undergoing dissolution tests.	Range of tablets manufactured in Shanghai.
Boehringer's newly designed metered dose inhaler will be manufactured at the Shanghai plant.	Boehringer Ingelheim will produce their most popular products at the Shanghai plant, aimed at the Chinese market.

Celltrion Biopharmaceutical Plant, Incheon
Artist impression of the new Celltrion Biopharmaceutical Plant in Incheon, South Korea.	The plant includes four independent trains of bioreactors; each train comprises 20L, 100L, 500L, 2,500L inoculum seed reactors and a 12,500L production bioreactor.	The new facility will start production with therapeutic monoclonal antibodies as a custom manufacturing facility for third parties.
The plant is to be used for the production of vaccines (particularly for AIDS and anthrax) and also for the production of therapeutic proteins.	HIV budding.	Anthrax Bacillus.
Anthrax protection.	Anthrax toxins.	One of the large bioreactors in the Celltrion facility.
The Celltrion building, which is soon to be expanded so that the facility will have a capacity of 230,000l.	Work underway in the research section of the company.

Chengdu Vaccine Plant
The new vaccine needs only one dose to give excellent protection.	The danger areas for Japanese encephalitis cover a lot of the Far East.	A mosquito laying eggs in water.
A child suffering from the disease in an Indian medical centre.	Paddy fields provide a perfect breeding ground for the disease vector.	The Mosquito that can spread the disease in exactly the same way as malaria.

Chugai Pharmaceutical Bulk Antibody
The Utsunomiya plant will be crucial in establishing Chugai as one of the largest potential commercial suppliers of treatments such as MRA, a humanised anti-IL-6 receptor monoclonal antibody (Atlizumab) indicated for rheumatoid arthritis.	Some of the process equipment supplied by Amersham Biosciences.	Bioreactors installed at the new phase one facility.
Granocyte, an important product for Chugai produced at the Usunomiya plant.	A microscopic view of multiple myeloma, a condition the new MRA antibody drugs will be designed to treat.	A healthy red blood cell count. One of Chugai's products is erythropoietin, a hormone that regulates the quantity of red blood cells in the body.
A researcher at Chugai Pharmaceutical working on new antibody technology.

Daiichi Asubio Pharma New Bio Plant (NBP), Gunma Prefecture
An exterior view of the new facility.	An exterior view of the new NBP.	Some of the equipment installed in the manufacturing area.
A view of the administrative area of the NBP.	Showing the exterior of the NBP.	A group of natriuretic peptides, some of which may well form part of future therapies for Asubio.

Daiichi Pharmaceutical Company
An overview of the Daiichi facilities.	Daiichi Pharmaceuticals' New Facility in Beijing, China.	Health expenditure as a percentage of GDP in China.

Dishman Pharma API Facility, Bavla, Ahmedabad
The Ahmedabad facility was commissioned in January 2010 and will be built in three phases.	Oncology APIs and other HiPo products will be produced by Dishman at the Indian site.	Each phase of the construction will build manufacturing cells with reactors for making certain pharmaceutical products.
The API facility is fully equipped to handle products with the required containment at all stages.	Process technology at the Dishman facility includes a reactor charging glovebox.	The Ahmedabad facility can accommodate up to four independent HiPo handling cells with capacity for three reactors.

Eskayef Bangladesh Ltd, Dhaka, Tongi
Eskayef is based in Dhaka, Bangladesh.	Dhaka is the industrial capital of Bangladesh and Eskayef has built the new plant in the Tongi industrial estate, on the outskirts of the city.	Salbutamol is one of the company's most recent offerings, launched in 2006.
Bird flu is a concern in Asia and Eskayef has recently released a preventative against the disease.	The company produces a wide variety of drugs for the domestic market but is now going to move into European markets.

GE Healthcare Shanghai Pharmaceutical Manufacturing Plant,
Nycomed Amersham plc's New Facility in Shanghai, China.	Chart showing health expenditure in proportion to GDP.	The Pharmadule method involves the construction of individual modules like this which are then shipped out to the facility site.
The modular construction allows for easy expansion. This is important as Nycomed Amersham are likely to want to expand if the Chinese joint venture is as successful as is hoped.	The construction of the modules in Sweden allows them to be tested before shipment.	MRI brainscan image.

Glaxo Wellcome Anti-Infective Drugs Plant,
The Glaxo Wellcome plant produces new anti infectives drugs including a treatment for hepatitis B.	The Suzhou plant will be completed in 2001.	Glaxo Welcome's new Facility in Suzhou of Jiangsu, China.
Pie chart showing health expenditure in China.

LG Chemical Pharmaceutical Plant,
Location of Iksan plant.	The facility was expanded further in 2001–2002.	The structure of the Factive molecule.
Factive tablet and packets.

Lonza Niacinamide Production Facility,
The niacinamide project was commissioned in the last half of 1999 at a cost of $30 million.	Production building and warehouse at the plant in the south western region of South Korea.	The Chinese plant is part of a wider expansion plan of Lonza, which is seeing investment in manufacturing facilities in Switzerland, the USA and China.
Analytical lab for raw materials intermediates and final products.

Nippon Shinyaku Corporation
A map of Odawara.	Nippon Shinyaku Corporation's Plant in Odawara of Kanagawa, Japan.	The pie diagram shows the level of spending on health in Japan, as a percentage of GDP.

Novartis Institute of BioMedical Research,
Novartis is expanding its research facilities in China to tackle diseases prevalent in the country.	The CNBIR combines the latest drug discovery methods with traditional Chinese medicine.	Because of a change in lifestyle choices and urbanisation, chronic diseases are becoming more prevalent in China.

Novartis Pharmaceutical Development Centre,
Novartis has opened its new pharmaceutical manufacturing centre in the Changshu Economic Development Zone in China.	The facility has been set up to mainly produce APIs and intermediates.	State-of-the-art equipment provided by suppliers from China and overseas was installed at the Novartis facility.
Novartis chose to locate the facility in Changshu for a number of reasons, including its proximity to the Yangtze River.	The facility's main focus will be on Novartis drugs addressing patient needs in the therapeutic areas of hypertension, hepatitis B and oncology, which have a high incidence in China.	The Novartis Changshu centre was designed by SINOPEC Shanghai Engineering.

Novo Nordisk Plant Expansion Tianjin
Module for the new facility being hoisted into position.	The NovoPen 3 which will be produced at the new facility.	The NovoPen system uses extra fine needles.
Some of the pens use a disposable cartridge system and some are completely disposable.	The patient uses a dial on the pen to set the correct dosage of insulin to be administered.	Insulin molecule peptide components.

Roche Vitamin Plant,
Location Map of Roche's Shanghai pharmaceuticals plant.

ScinoPharm Bulk Pharmaceutical Plant,
ScinoPharm completed its API contract manufacturing plant in 2001 and an adjacent biotechnology plant in 2004.	Part of the large-scale API production facilities at ScinoPharm.	ScinoPharm was first set up in the US in 1994 as a bulk material subcontractor to major pharmaceutical firms.
As the global pharmaceutical industry becomes more diverse, many international drug makers are subcontracting the production of bulk pharmaceuticals to other companies on an outsourcing basis.	The plant has seven operating areas designed to handle any scale of production from kilo-lab scale 1kg up to a commercial scale of 100kg.	The plant produces a range of products, including Paclitaxol, Mestranol, Riluzole, Flumenazil and Lisinopril.
The administration building, technology building, waste water processing plant and main factory for the first stage production lines of the 6.6ha facility were completed in the first phase of the project.	The plant complex in December 1999.

Shanghai CP Guojan
CPGJ has its headquarters in Shanghai.	Shanghai was chosen for CPGJ's headquarters as it is an industrial city with excellent infrastructure and transport links.	The new commercial-scale plant at Zhangjiang Hi-Tech Park in Shanghai will produce antibody products.
Shanghai has developed into an industrial centre and with the help of companies such as CPGJ is set to form a biotech hub to rival Singapore.	CPGJ has around ten antibody treatments either ready for commercialisation or in clinical trials.

Shanghai Roche Pharmaceuticals, Shanghai
Cellcept as produced at the new plant (suspension form).	The plant has high containment glove boxes.	Shanghai is one of the wonders of the modern industrial age it is a power house of Chinese manufacturing of all types.
The molecular structure of Cellcept.	Xeloda tablets are also produced at the new high containment plant.

Sumitomo Pharmaceutical Manufacturing Plant,
Health Expenditure as a percentage of GDP in Japan.	Location of Sumitomo Pharmaceuticals plant in Ibaraki.	Location of the Sumitomo Pharmaceuticals Ehime Bio facilities.

Taiyo Pharmaceutical Industry, Contract Manufacturing Plant
The facility has state of the art equipment designed by the company for its own specific requirements.	The Unit Factory building in Takayama City on the Taiyo Pharmaceutical Industry campus.	The company has moved into contract filling and packaging of pre-filled syringes with a big investment in a new manufacturing facility.
Taiyo also manufactures generic antibiotics and vitamins.	The plant is in the Takayama Prefecture in Japan.

Browse Projects